Improving heart blood flow after heart attacks

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of different imaging-guided approaches for coronary revascularization in patients experiencing anterior wall ST-segment elevation myocardial infarction (STEMI). Ninety patients will be randomized into three groups: one receiving optical coherence tomography (OCT) guidance, another receiving 60 MHz high-definition intravascular ultrasound (HD-IVUS) guidance, and a control group receiving standard angiography guidance. The study aims to assess myocardial microcirculation improvement post-procedure using TIMI myocardial perfusion frame count (TMPFC) and cardiac MRI. The trial is designed to enhance treatment outcomes for patients undergoing primary percutaneous coronary intervention (PCI).

Why it matters

Who can join: the full rules

Inclusion Criteria:

Clinical Inclusion Criteria:

1. Subjects aged ≥18 years;
2. Initial diagnosis of anterior wall ST-segment elevation myocardial infarction, with symptoms occurring within 6 hours, and undergoing primarypercutaneous coronary intervention (PCI);
3. Subjects (or legal representatives) who understand the study requirements and treatment procedures and provide signed informed consent.

Imaging Inclusion Criteria (Visual Estimation):

1. Target lesion is the culprit lesion, located in the native coronary artery, with a visually estimated reference vessel diameter (RVD) between 2.25 mm and 4.0 mm;
2. Culprit segment of the infarct-related artery (IRA) is located between the origin of the left anterior descending (LAD) artery and the emergence of the second diagonal branch (D2);
3. After pre-treatment , the degree of stenosis in the LAD is ≤90%, and TIMI flow is grade 3.

Exclusion Criteria:

Clinical Exclusion Criteria:

1. History of coronary artery bypass grafting (CABG);
2. Known history of myocardial infarction or PCI;
3. Previous thrombolytic therapy before PCI;
4. Severe liver or kidney dysfunction, severe valvular heart disease, chronic obstructive pulmonary disease, etc.;
5. Contraindications to magnetic resonance imaging;
6. Allergy to gadolinium contrast agents and/or accompanying medications for devices or procedures (e.g., any component of drug-eluting stents, all P2Y12 inhibitors, or aspirin);
7. Expected lifespan of the subject less than 12 months;
8. Pregnant or lactating females;
9. Other subjects deemed unsuitable for participation in the study by the investigator.

Imaging Exclusion Criteria (Visual Estimation):

1. Presence of lesions requiring intervention other than the target lesion at baseline surgery;
2. No protected left main coronary artery disease (visual estimate of stenosis \>50%);
3. Diffuse severe calcification (\>20 mm) or chronic total occlusion in the major coronary vessels (LCX, RCA);
4. Severe coronary artery tortuosity (\>45°) or calcification (\>270°), or other conditions that may interfere with the use of intravascular imaging.

Where it's running

• The 2nd Affiliated Hospital of Harbin Medical University
  Harbin, Heilongjiang, China Recruiting

Study contacts

• Principal investigator: Bo Yu, M.D.; Ph.D. — The Second Affiliated Hospital of Harbin Medical University
• Study coordinator: Xingtao Huang, MD
• Email: dr_huangxingtao@163.com
• Phone: +86-13796626722

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding heart artery disease using biomarkers and imaging in Oxford

  Researchers in Oxford are testing how biomarkers and advanced imaging can help explain why some heart artery plaques are unstable and how this affects heart damage after a heart attack.

  Recruiting University of Oxford · Oxford · NCT07772570

• Non-stenting approach for acute heart attack with non-severe narrowing

  A large, multicenter trial will test whether standard medical therapy alone works as well as using drug-eluting stents in patients with a recent heart attack and a culprit artery with mild to moderate narrowing.

  Recruiting Harbin Medical University · Harbin, Heilongjiang and 47 other locations · NCT07567625

• Oral Paclitaxel Plus Fruquintinib as Second-Line Treatment in Advanced Gastric/GEJ Cancer

  This trial tests whether taking an oral paclitaxel solution together with fruquintinib, chosen by the investigator, can help adults with advanced or metastatic stomach or gastroesophageal junction cancer after first-line therapy.

  Recruiting at 15 sites Harbin Medical University · Fuzhou, Fujian and 14 other locations · NCT07552402

• Understanding diagnosis, prognosis, and causes of panvascular disease

  This project will collect medical records, DNA samples, and follow-up from adults with panvascular disease to see if linking clinical and genetic data can reveal causes and suggest better treatments.

  Recruiting Harbin Medical University · Harbin, Heilongjiang · NCT07151183

• Health of older Chinese seasonal migrants

  This project will follow older adults who move seasonally between cold Heilongjiang and tropical Hainan to see if their migration patterns affect heart, metabolic, and aging-related health.

  Recruiting Harbin Medical University · Harbin, Heilongjiang · NCT07124949

• Targeted PET/CT Imaging for Non-Small Cell Lung Cancer

  This study is testing a new imaging agent to see if it can help identify which patients with non-small cell lung cancer might benefit from targeted therapies based on a specific cancer marker.

  Recruiting Harbin Medical University · Harbin, Heilongjiang · NCT06911697

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.